Efficacy and optimal treatment sequence of Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma

DOI Web Site Web Site 1 Citations 84 References
  • Hiramine Yasunari
    Department of Internal Medicine, Kagoshima Kouseiren Hospital Department of Digestive and Lifestyle-Related Disease, Kagoshima University Graduate School of Medical and Dental Sciences
  • Tamai Tsutomu
    Department of Digestive and Lifestyle-Related Disease, Kagoshima University Graduate School of Medical and Dental Sciences
  • Imamura Yasushi
    Department of Internal Medicine, Kagoshima Kouseiren Hospital
  • Baba Yoshirou
    Department of Internal Medicine, Kagoshima Kouseiren Hospital
  • Hiwaki Takuya
    Department of Internal Medicine, Kagoshima Kouseiren Hospital
  • Yamashita Hiroka
    Department of Internal Medicine, Kagoshima Kouseiren Hospital Department of Digestive and Lifestyle-Related Disease, Kagoshima University Graduate School of Medical and Dental Sciences
  • Sho Yukihiko
    Department of Internal Medicine, Kagoshima Kouseiren Hospital
  • Tahara Kenji
    Department of Internal Medicine, Kagoshima Kouseiren Hospital
  • Kanetsuki Ichiro
    Department of Radiology, Kagoshima Kouseiren Hospital
  • Tsubouchi Hirohito
    Department of Digestive and Lifestyle-Related Disease, Kagoshima University Graduate School of Medical and Dental Sciences

Bibliographic Information

Other Title
  • 進行肝細胞癌に対するソラフェニブと肝動注化学療法の有効性および治療法選択
  • シンコウ カン サイボウガン ニ タイスル ソラフェニブ ト カンドウ チュウ カガク リョウホウ ノ ユウコウセイ オヨビ チリョウホウ センタク

Search this article

Description

We examined whether treatment sequence and secondary therapy affected prognosis in advanced hepatocellular carcinoma (HCC) of Child-Pugh A without metastasis. The study included 148 patients: 83 who primarily received Hepatic Arterial Infusion Chemotherapy (HAIC), 53 who received Sorafenib, and 12 with best supportive care (BSC). These treatment groups were stratified by presence (+)/absence (-) of secondary therapy. Although a significant difference in the response rate was found between the HAIC group and the Sorafenib group, there were no differences in disease control rate and survival. Additionally, both prolonged survival compared to the BSC group. Sorafenib (+) group showed the highest cumulative survival rate, which was an independent prognostic factor in multivariate analysis. Furthermore, the initial Sorafenib dose per body weight was a contributing factor for treatability with HAIC as secondary therapy subsequent to Sorafenib. The prognosis of advanced HCC might be improved by Sorafenib per body weight followed by HAIC.<br>

Journal

  • Kanzo

    Kanzo 54 (4), 233-248, 2013

    The Japan Society of Hepatology

Citations (1)*help

See more

References(84)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top